Navigation Links
FDA Approves Amyvid™ (Florbetapir F 18 Injection) for Use in Patients Being Evaluated for Alzheimer's Disease and Other Causes of Cognitive Decline
Date:4/6/2012

INDIANAPOLIS, April 6, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Avid Radiopharmaceuticals, Inc., a wholly owned subsidiary of Lilly, today announced the U.S. Food and Drug Administration (FDA) approval of Amyvid™, a radioactive diagnostic agent indicated for brain imaging of beta-amyloid plaques in patients with cognitive impairment who are being evaluated for Alzheimer's Disease and other causes of cognitive decline.[1] Amyvid binds to amyloid plaques, a hallmark characteristic of Alzheimer's Disease,[2],[3],[4] and is detected using PET scan images of the brain.[1]

A negative Amyvid scan indicates sparse to no amyloid plaques are currently present, which is inconsistent with a neuropathological diagnosis of Alzheimer's Disease and reduces the likelihood that a patient's cognitive impairment is due to Alzheimer's Disease.[2] [5] A positive Amyvid scan indicates moderate to frequent amyloid plaques are present; this amount of amyloid plaque is present in patients with Alzheimer's Disease, but may also be present in patients with other types of neurologic conditions and in older people with normal cognition.[1], [4], [6]

It's important to note that Amyvid is an adjunct to other diagnostic evaluations. A positive Amyvid scan does not establish a diagnosis of Alzheimer's Disease, or other cognitive disorder. Additionally, the safety and effectiveness of Amyvid have not been established for predicting development of dementia or other neurologic condition, or monitoring responses to therapies.[1]

Alzheimer's Disease is one of several possible causes of cognitive decline. Alzheimer's Disease and other causes of cognitive impairment share many overlapping symptoms including memory, visuospatial ability, executive function, behavior and language deficiencies.[4],[7] Because a definitive diagnosis of Alzheimer's Disease is usually determined u
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. U.S. FDA Approves First and Only Oral Contraceptive Demonstrated to Treat Heavy Menstrual Bleeding (HMB)
2. FDA Approves Additional Manufacturer of Methoxsalen
3. FDA Approves New Skin Cancer Drug First Tested in Arizona by Scottsdale Healthcare and TGen
4. FDA approves Novartis drug Gleevec® label recommending extending treatment to three years for certain GIST patients after surgery
5. FDA Approves Gleevec For Expanded Use in Patients With Rare Gastrointestinal Cancer
6. FDA Approves Kalydeco to Treat Rare Form of Cystic Fibrosis
7. ASAM Approves Prescription Drug Policy
8. FDA Approves Picato® (ingenol mebutate) Gel, the First and Only Topical Actinic Keratosis (AK) Therapy With 2 or 3 Consecutive Days of Once-Daily Dosing
9. FDA Approves Shared REMS (Risk Evaluation and Mitigation Strategy) Program for all TIRF (Transmucosal Immediate Release Fentanyl) Pain Treatments
10. FDA Approves EDARBYCLOR (azilsartan medoxomil and chlorthalidone) for the Treatment of Hypertension
11. FDA Approves Mechanical Cardiac Assist Device for Children With Heart Failure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)...  IRIDEX Corporation (NASDAQ: IRIX ) today announced ... results after the market closes on Thursday, May ... Company will host a conference call with the investment ... Thursday, May 7, 2015 to discuss the ... Interested parties may access the live conference call ...
(Date:4/30/2015)...   Regulus Therapeutics Inc . (NASDAQ: RGLS ... of innovative medicines targeting microRNAs, today announced that it ... ended March 31, 2015 on Thursday, May 7, 2015, ... Regulus will host a conference call and webcast on ... Time to discuss its first quarter 2015 financial results ...
(Date:4/30/2015)... FRANCISCO, April 30, 2015  Nektar Therapeutics (Nasdaq: ... first quarter ended March 31, 2015. ... 2015 were $325.8 million as compared to $262.8 million ... marketable securities at March 31, 2015 includes a $100.0 ... for the first commercial sale of Movantik™(naloxegol) in the ...
Breaking Medicine Technology:IRIDEX Announces First Quarter 2015 Conference Call and Release Date 2Regulus Announces Timing for First Quarter 2015 Financial Results Webcast and Conference Call 2Regulus Announces Timing for First Quarter 2015 Financial Results Webcast and Conference Call 3Nektar Therapeutics Reports Financial Results for the First Quarter of 2015 2Nektar Therapeutics Reports Financial Results for the First Quarter of 2015 3Nektar Therapeutics Reports Financial Results for the First Quarter of 2015 4Nektar Therapeutics Reports Financial Results for the First Quarter of 2015 5Nektar Therapeutics Reports Financial Results for the First Quarter of 2015 6Nektar Therapeutics Reports Financial Results for the First Quarter of 2015 7Nektar Therapeutics Reports Financial Results for the First Quarter of 2015 8Nektar Therapeutics Reports Financial Results for the First Quarter of 2015 9Nektar Therapeutics Reports Financial Results for the First Quarter of 2015 10Nektar Therapeutics Reports Financial Results for the First Quarter of 2015 11Nektar Therapeutics Reports Financial Results for the First Quarter of 2015 12
... Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR ) today announced ... the Jefferies 2012 Global Healthcare Conference in New York, NY. ... Presentation date: Monday, June 4, 2012 , Presentation time: 12:30 ... 30-day archive of these presentations will be available at http://ir.avanir.com ...
... - Hospital Universitari Vall d,Hebron Research Institute in Barcelona ... an open label phase 2 study evaluating the overall ... treatment of cirrhosis of the liver and upper GI ... patients demonstrated that OCR-002 is well tolerated and provided ...
Cached Medicine Technology:Preliminary Phase 2 Data of Ocera Therapeutics' OCR-002 for the Treatment of Liver Cirrhosis and Upper GI Bleeding Show Potent Ammonia Reduction 2Preliminary Phase 2 Data of Ocera Therapeutics' OCR-002 for the Treatment of Liver Cirrhosis and Upper GI Bleeding Show Potent Ammonia Reduction 3
(Date:5/2/2015)... May 02, 2015 “ Peachtree Audio ... monthly Tech Report, which features the latest and coolest ... expert and special reporter for NewsWatch, conducted the review ... audio equipment. , Music is an important part ... be pampered and given the royal treatment. Peachtree Audio ...
(Date:5/2/2015)... (PRWEB) May 02, 2015 ZoomCare, the ... has submitted plans to offer its new healthcare insurance ... The ZOOM+ Personal Health Insurance System is the nation’s ... to enhance human performance. ZOOM+ Personal Health Insurance was ... delivery system that are subject to review and regulation ...
(Date:5/1/2015)... Pioneer Millworks, the largest reclaimed wood ... their reclaimed wood products at the 27th annual International ... in NYC this May. Their newest offerings, Vat 35, ... texture and color to North America's platform for global ... and color in the design world and we're excited ...
(Date:5/1/2015)... Costa Mesa, CA (PRWEB) May 01, 2015 ... sponsor at the Cerner Southeast Regional User Group (RUG) ... 2015. The Cerner Southeast Regional User Group Conference provides ... access to vendors who support all aspects of electronic ... innovative use of Cerner software applications. , In addition ...
(Date:5/1/2015)... Yorba Linda, CA (PRWEB) May 01, 2015 ... of our genetic makeup and the interplay of genes ... Keeping up with developments can be daunting. , LabRoots, ... sciences and clinical diagnostics professionals, will soon host its ... Genomics. , At BioConference Live Genetics and Genomics ...
Breaking Medicine News(10 mins):Health News:Affordable High-End Audio Equipment was Featured on NewsWatch Television 2Health News:ZoomCare Applies to be on Oregon Exchange 2Health News:Intensely Textured Reclaimed Wood to be Unveiled at ICFF in NYC by Pioneer Millworks 2Health News:Intensely Textured Reclaimed Wood to be Unveiled at ICFF in NYC by Pioneer Millworks 3Health News:TROY Healthcare to Exhibit at the Cerner Southeast Regional User Group Conference 2Health News:TROY Healthcare to Exhibit at the Cerner Southeast Regional User Group Conference 3Health News:Recent Advances in Genetics and Genomics: A BioConference Live 2015 Virtual Event 2Health News:Recent Advances in Genetics and Genomics: A BioConference Live 2015 Virtual Event 3
... 50 years medical research has been vetted through the ... reviewers to determine whether work merits publication. A study ... and their influence on journal editors who are the ... not. "Published research is becoming a more ...
... Small study found technique restored some muscle function for months ... in using gene therapy to restore some muscle function in ... is the first time such a feat has been performed ... at the annual meeting of the American Society of Gene ...
... Poorman or ... ... personality Jim “Poorman” Trenton has the wavefront Lasik procedure with Los Angeles Lasik ... most noted for his work on Loveline the nightly radio talk show on KROQ, which ...
... ... visibility at the management and board level , ... MetricStream, Inc., the market leader in enterprise-wide Governance, ... with AEI, an emerging markets energy infrastructure company, to provide MetricStream’s GRC Platform and ...
... program reduced cardiovascular disease-related medical and hospital costs, ... national company with 30,000 employees, developed the program ... cardiovascular disease when compared to national benchmarks and ... time, the program included a variety of interventions, ...
... for these two diseases? Or does diabetes cause processes in the ... still unclear why diabetics have a higher rate of cancer than ... In order to precisely identify the types of cancer in ... colleagues in Sweden and the United States to carry out the ...
Cached Medicine News:Health News:To publish or not to publish? That is the question 2Health News:Gene Therapy Shows Promise for Muscular Dystrophy 2Health News:Gene Therapy Shows Promise for Muscular Dystrophy 3Health News:'Poorman' Has Lasik with Dr. Khanna 2Health News:MetricStream Enters into Agreement to Provide Enterprise Risk Management Software Solution to AEI 2Health News:Increased cancer risk of people with type 2 diabetes 2
Taper with blunt tip. Stainless steel. Round knurled handle with polished finish. Taper : Medium 23 mm. Overall length: 3.9 inches....
Size 2 dilator. Stainless steel. Round knurled handle with polished finish. Overall length: 4 inches....
The interface spatula can be used when irregular interface adherence occurs. By beginning at the point of a dissected edge and sweeping in uniplanar motion towards the area of adherence, the flap can...
Duckbilled spatula designed to enter a side-port stab incision with tip broad enough to efficiently manipulate the lens nucleus in the anterior chamber. Spatula is useful for rotating and cracking th...
Medicine Products: